Role of DOACs in APS treatment

Role of DOACs in APS treatment

What are direct oral anticoagulants (DOACs) and what is their role in APS treatment?

DOACs are non-vitamin K antagonist oral anticoagulants that bind directly to specific clotting factors. Dabigatran is a factor IIa inhibitor, whereas rivaroxaban, apixaban, and edoxaban are factor Xa inhibitors. They have a rapid onset of action and relatively short half-life. They should not be used in patients with a CrCl <30 mL/minute. There is limited data on their use in APS patients. One study (Lancet Haematol 2016; 3: e426-e436) reported that rivaroxaban was noninferior to warfarin for secondary prevention of venous thromboembolism in a 6-month trial. A concern is that due to the short half-life of DOACs, an APS patient will be at risk for a clot if they miss one dose. With the limited data available, DOACs are not recommended as the first-line therapy for APS patients. If used, they should not be used in patients with arterial clots.

Pearl : patients on DOACs will have a false-positive LA test. Need to repeat test off DOAC (i.e., hold DOAC for 24–48 hours).

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856